CGEM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
52.6M
-8.1%
57.3M
+6.6%
53.7M
-2.8%
55.3M
-0.6%
55.6M
R&D
40.2M
-9.6%
44.4M
+5.5%
42.1M
-1.9%
42.9M
+2.3%
42.0M
SG&A
12.4M
-3.0%
12.8M
+10.7%
11.6M
-6.0%
12.3M
-9.6%
13.6M
Operating Income
-52600000
+8.1%
-57254000
-6.6%
-53697000
+2.8%
-55259000
+0.6%
-55595000
EBITDA
-52547000
+8.1%
-57175000
-6.6%
-53618000
+2.8%
-55180000
+0.6%
-55516000
Net Income
-49388000
+8.0%
-53704000
-8.1%
-49661000
+2.1%
-50713000
-0.2%
-50610000
EPS (Basic)
$-0.74
+14.9%
$-0.87
-16.0%
$-0.75
-53.1%
$-0.49
+36.4%
$-0.77
EPS (Diluted)
$-0.74
+14.9%
$-0.87
-16.0%
$-0.75
-53.1%
$-0.49
+36.4%
$-0.77
Shares (Diluted)
64.4M
+4.7%
61.5M
+1.7%
60.5M
+2.1%
59.2M
+0.2%
59.1M
Cullinan Therapeutics (CGEM) — Financials